Company intelligence / Profile preview

KromaTiD

Longmont, Colorado, United Stateskromatid.com ↗

Ownership: Private
Employees: ~28
Development stage: Commercial

Overview

KromaTiD provides advanced single-cell cytogenetic analysis platforms to assess genome integrity and structural variation in cell and gene therapy products. Their technologies are used from early research through clinical trials to support safety data packages for regulatory filings. The company’s platforms are trusted by organizations such as NASA for high-resolution detection of complex genomic rearrangements that conventional methods may miss. No direct clinical results as they do not sponsor therapeutic programs.

Therapeutic areas: Other
Modalities: Not applicable (service/platform company; does not develop therapeutics directly)
Industry: Molecular Diagnostics

Partnerships

NASA (for spaceflight-related radiation damage studies using their platform)

Beyond the preview

Go deeper on KromaTiD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KromaTiD.

Explore the full profile